Peer-influenced content. Sources you trust. No registration required. This is HCN.

Psychiatrist.comCannabidiol for Treatment-Resistant Anxiety Disorders in Young People: An Open-Label Trial

Treatment resistance affects nearly half of all young people experiencing moderate-to-
severe anxiety. In this 12-week open-label trial, patients received add-on CBD after no
clinical improvement on therapy with CBT and/or antidepressant medication. There was
a more than 40% reduction in mean OASIS scores and no serious or unexpected
adverse events.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form